-
公开(公告)号：US20240118266A1
公开(公告)日：2024-04-11
申请号：US18299415
申请日：2023-04-12
申请人： UCL Business PLC
发明人： Samuel Janes , Krishna Kolluri , Ultan McDermott , Neelam Kumar
IPC分类号： G01N33/50 , A61K31/7105 , A61P35/00 , G01N33/574
CPC分类号： G01N33/5017 , A61K31/7105 , A61P35/00 , G01N33/5023 , G01N33/574 , G01N2496/05 , G01N2500/02 , G01N2500/10 , G01N2510/00 , G01N2800/52
摘要： The invention relates to cell death of cancer cells, and in particular to biomarkers that may be used to identify cancer cells that are sensitive to death receptor ligand (DRL)-induced cell death. The invention also extends to prognostic methods and kits for identifying cancer cells that are sensitive to DRL-induced cell death. The invention further extends to novel compositions and therapeutic methods using such compositions for treating cancer.
-
公开(公告)号：US11789012B2
公开(公告)日：2023-10-17
申请号：US16333590
申请日：2017-09-15
申请人： UCL Business PLC
发明人： Samuel Janes , Krishna Kolluri , Ultan McDermott , Neelam Kumar
IPC分类号： G01N33/50 , A61P35/00 , A61K31/7105 , G01N33/574
CPC分类号： G01N33/5017 , A61K31/7105 , A61P35/00 , G01N33/5023 , G01N33/574 , G01N2496/05 , G01N2500/02 , G01N2500/10 , G01N2510/00 , G01N2800/52
摘要： The invention relates to cell death of cancer cells, and in particular to biomarkers that may be used to identify cancer cells that are sensitive to death receptor ligand (DRL)-induced cell death. The invention also extends to prognostic methods and kits for identifying cancer cells that are sensitive to DRL-induced cell death. The invention further extends to novel compositions and therapeutic methods using such compositions for treating cancer.
-
公开(公告)号：US11464745B2
公开(公告)日：2022-10-11
申请号：US16463728
申请日：2017-11-27
申请人： UCL Business PLC
发明人： Abdul Basit , Alvaro Goyanes , Simon Gaisford , Fabrizio Fina
IPC分类号： A61K9/20 , A61K9/00 , A61K9/16 , A61K9/70 , A61K31/167 , A61K31/606 , B33Y10/00 , B33Y30/00 , B33Y70/00 , B33Y80/00
摘要： A process for producing a solid pharmaceutical dosage formulation, said process comprising powder bed fusion selective laser 3-dimensional printing of a mixture comprising: (a)a drug; and (b)an excipient; whereinat least one of said drug and said excipient absorbs electromagnetic radiation at a wavelength emitted by the laser; or (a)a drug; (b)an excipient; and (c)an absorbent material which absorbs electromagnetic radiation at a wavelength emitted by the laser.
-
公开(公告)号：US11406690B2
公开(公告)日：2022-08-09
申请号：US16588130
申请日：2019-09-30
摘要： The present disclosure provides methods of generating multiplexed genetically modified animals, for example, porcine endogenous retrovirus (PERV)-inactivated pigs. The disclosure also provides methods of improving the birth rate of multiplexed genetically modified animals. In some embodiments, the present closure is concerned with the generation and utilization of porcine cells in which porcine endogenous retroviral (PERV) elements have been inactivated. In sonic embodiments, the PERV-free or PERV-reduced porcine cells are cloned to produce porcine embryos. In some embodiments, the PERV-free or PERV-reduced embryos may be grown into adult swine from which organs and/or tissues may be extracted and used for such purposes as xenotransplantation into non-porcine animals such as humans.
-
公开(公告)号：US20220006264A1
公开(公告)日：2022-01-06
申请号：US17374392
申请日：2021-07-13
申请人： UCL Business PLC
发明人： Mingchu TANG , Mengya LIAO , Siming CHEN , Jiang WU , Alwyn SEEDS , Huiyun LIU
摘要： A semiconductor device comprising a nominally or exactly or equivalent orientation silicon substrate on which is grown directly a
-
公开(公告)号：US20210207457A1
公开(公告)日：2021-07-08
申请号：US17211443
申请日：2021-03-24
摘要： A mass balance is determined for periodic final inlet component flow rates entering Gas Oil Separation Plants (GOSPs). For transfers between GOSPs, constraints are calculated based on capacities of pipelines and a single direction of transfer. Calculated final inlet component flow rates are maintained for each GOSP within the calculated maximum and minimum GOSP pipeline capacities. Raw materials and intermediate and final states are formulated. Consumed power is calculated in in linear form using known flow rates per equipment. Investment decisions are performed with respect to swing pipelines and new equipment and a final net present value (NPV) is calculated with an overall objective function.
-
公开(公告)号：US11040101B2
公开(公告)日：2021-06-22
申请号：US16385591
申请日：2019-04-16
申请人： UCL BUSINESS PLC
发明人： Nikolitsa Nomikou
摘要： The present invention relates generally to methods and materials for use in photothermal or sonodynamic therapy. The invention novel nanoparticles for use in delivering sensitizers to solid tumour target, wherein the nanoparticles are composed of a polymers or co-polymer of monomers linked by peptide bonds, wherein the polymer or co-polymer comprises one or both of glutamate or derivatised glutatamic acid, and optionally a further, different, monomer which is a naturally occurring amino acid or synthetic monomer having a side chain group, wherein the polymer or co-polymer is not composed only of glutamate. The pendant groups and/or side chains of the polymer or co-polymer interact non-covalently with the sensitizer.
-
公开(公告)号：US20210052496A1
公开(公告)日：2021-02-25
申请号：US16961188
申请日：2019-01-10
申请人： UCL Business PLC
发明人： Stephen Hart , Aristides Tagalakis
IPC分类号： A61K9/127 , A61K31/7088 , A61K38/17 , A61P35/00
摘要： A non-viral delivery complex comprising a cationic core which is a nanoparticle comprising a peptide having a polycationic nucleic acid binding component, a cleavable spacer element and a cell surface receptor binding component; a nucleic acid and optionally a cationic lipid; and an anionic liposomal coating surrounding the cationic core, said coating comprising lipids from a subject's cells. Also related formulations, uses and methods.
-
公开(公告)号：US20210000977A1
公开(公告)日：2021-01-07
申请号：US16622800
申请日：2018-06-15
申请人： UCL BUSINESS PLC
发明人： Stephanie SCHORGE , Matthew Charles WALKER , Dimitri M. KULLMANN , Albert SNOWBALL , Elodie CHABROL
IPC分类号： A61K48/00 , C12N15/86 , C07K14/705 , A61K38/17 , A61P25/08 , C12Q1/6876
摘要： The invention provides expression vectors, nucleic acids, vector particles and methods of treatment involving these vector particles, comprising an engineered KCNA1 gene encoding an edited Kv1.1 potassium channel, as well as methods of confirming the presence of engineered KCNA1 mRNA in a cell. The features of the engineered KCNA1 gene combine to advantageously enhance the translation and activity of the Kv1.1 protein and improve detection of KCNA1 gene expression in a cell and can be used for example in the treatment of epilepsy and similar neurological disorders.
-
公开(公告)号：US20200316372A1
公开(公告)日：2020-10-08
申请号：US15733276
申请日：2018-12-11
发明人： Rizwan BASHIRULLAH , Gerald Edwin HUNSBERGER , Matteo DONEGA , Daniel CHEW , David Holder , Kirill ARISTOVICH
摘要： A nerve interface device including at least one cuff portion having an assembled position in which the cuff portion forms at least part of a passageway for receiving a nerve along a longitudinal axis passing through the passageway; and first and second rings of electrodes mounted on the at least one cuff portion, each ring of electrodes including a plurality of electrodes. Each electrode in the first ring has a corresponding longitudinally-aligned electrode in the second ring so as to form a plurality of pairs of electrodes spaced apart from each other along the longitudinal axis. The plurality of pairs of electrodes includes at least a first pair of electrodes, the first pair of electrodes mounted on the at least one cuff portion. The at least one cuff portion includes an asymmetric configuration about a central axis perpendicular to the longitudinal cuff axis.
-
-
-
-
-
-
-
-
-
搜索结果
357 条记录 (耗时 0.027 秒)
